A Quality of Life (QOL) Assessment of Genitourinary (GU) Toxicity at Five Years for Prostate Cancer Patients Undergoing Different Radiation Treatment Modalities

2010 ◽  
Vol 78 (3) ◽  
pp. S601
Author(s):  
K.A. Saputo ◽  
A. Calcaterra ◽  
M. Balasubramaniam ◽  
G. Boyea ◽  
C. Flynn ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Cancer Patients ◽  
Radiation Treatment ◽  
Treatment Modalities ◽  
Gu Toxicity

A quality of life (QOL) assessment of prostate cancer patients undergoing different radiation treatment modalities

Brachytherapy ◽  
2006 ◽  
Vol 5 (2) ◽  
pp. 92
Author(s):  
K. Saputo ◽  
A. Calcaterra ◽  
G. Boyea ◽  
Michelle Wallace ◽  
Mamtha Balasubramaniam ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Cancer Patients ◽  
Radiation Treatment ◽  
Treatment Modalities

Factors affecting health-related quality of life among prostate cancer patients: A systematic review

2020 ◽  
Vol 26 (8) ◽  
pp. 1997-2010
Author(s):  
Sharon Odeo ◽  
Amsalu Degu
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Systematic Review ◽  
Sexual Function ◽  
Cancer Patients ◽  
Clinical Stage ◽  
Treatment Modalities ◽  
Functional Score ◽  
Incidence And Mortality

Introduction Prostate cancer is recognized as the leading cause of malignancy-related incidence and mortality in the male population. The treatment regimens have long-term effects detrimental to the patient's quality of life. Hence, this review was aimed to determine the overall HRQOL and its associated among prostate cancer patients. Methods The review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. The databases searched were PubMed, Embase, Google Scholar and Cumulative Index to the Nursing and Allied Literature (CINAHL), which provided articles that were critically examined, yielding 52 studies that met the inclusion criteria for the systematic review. Results Out of 52 studies, 30 studies reported poor overall HRQOL in various domains after prostate cancer treatment. Contrastingly, 15 studies reported good overall quality of life after treatment. Among the various domains, sexual function was the most grossly affected functional score by the treatment modalities of prostate cancer. Nonetheless, seven studies showed that the absence of a significant change in the overall quality of life after treatment. According to the studies, older age, comorbidities, higher clinical stage, higher Gleason score, greater cancer severity, African American race, impaired mental health, neoadjuvant hormonal therapy and lower level of education were the major poor predictors of HRQOL among prostate cancer patients. Conclusion The overall HRQOL in prostate cancer patients was generally poor in various functional domains after treatment. Among the various domains, sexual function was the most grossly affected functional score by the treatment modalities of prostate cancer.

A review of the effects of tobacco smoking on the treatment of prostate cancer

2020 ◽  
pp. 1-8
Author(s):  
Faiza Nuru ◽  
Ernest Osei ◽  
Rahil Kassim
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Smoking Cessation ◽  
Radiation Therapy ◽  
Cancer Patients ◽  
Tobacco Smoking ◽  
Treatment Efficacy ◽  
Treatment Modalities ◽  
Risk Of Cancer

Abstract Background: Prostate cancer is the most commonly diagnosed malignancy and the third leading cause of death among Canadian men. The standard treatment modalities for prostate cancer include prostatectomy, radiation therapy, hormonal therapy and chemotherapy or any combination depending on the stage of the tumour. However, several studies have reported that tobacco smoking at the time of diagnosis and during treatment can potentially impact treatment efficacy, outcome and patients quality of life after treatment. Materials and methods: This narrative literature review elucidates the impacts of tobacco smoking on prostate cancer progression, treatment efficacy, including its effects on prostatectomy, radiation therapy and chemotherapy, risk of cancer recurrence and mortality and quality of life after treatment. Furthermore, we discuss the importance of integrating a smoking cessation programme into the treatment regimen for prostate cancer patients in order to yield more favourable treatment outcomes, reduce risk of recurrence and mortality and increase the quality of life after treatment for prostate cancer patients. Conclusions: Smoking cessation is one of the most important interventions to prevent cancer and it is also essential after the diagnosis of prostate cancer to improve clinical outcomes. All prostate cancer patients should be advised to quit tobacco use since it can potentially improve treatment response rates and survival, as well as reduce the risk of developing treatment complications and potentially improve the quality of life after treatment. There are several benefits to smoking cessation and it should become an important component of the cancer care continuum in all oncology programmes, starting from prevention of cancer through diagnosis, treatment, survivorship and palliative care. Evidence-based smoking cessation intervention should be sustainably integrated into any comprehensive cancer programme, and the information should be targeted to the specific benefits of cessation in cancer patients.

Role of Erlotinib in Influencing the Quality of Life of Cancer Patients

2020 ◽  
Vol 07 ◽  
Author(s):  
Deepika Purohit ◽  
Parijat Pandey
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Cancer Patients ◽  
Kinase Inhibitors ◽  
Treatment Modalities ◽  
Pancreatic Cancers ◽  
Review Reports ◽  
Causes Of Deaths

Background:: Cancer is one of the significant causes of morbidity and mortality in patients globally. Lung cancer, among other cancers, remains to be one of the principal causes of deaths in both men and women. The most common type of lung cancer is the non-small-cell lung cancer (NSCLC). Apart from lung cancer, pancreatic cancer is also one of the common cancers currently. Objective:: The assessment of QoL in erlotinib-treated patients can also prove to be very useful in the establishment of this drug as the main treatment option for the patients with pancreatic and lung cancer. Methods:: Therapies that target EGFR-mediated signalling are the latest keystones for treating these two types of cancers. They comprise of two main treatment modalities: firstly, against the extracellular fields, that include monoclonal antibodies and secondly, mechanisms that create interferences in the signalling pathways, primarily the small molecule tyrosine kinase inhibitors. Results:: Quality of life (QoL) is one of the key advantages in erlotinib therapy over chemotherapy. Conclusion:: The present review reports the role of erlotinib in improving the quality of life of cancer patients especially in NSCLC and pancreatic cancers. The studies or trials establishing the relations between erlotinib and QoL are discussed in detail in this review.

Sign in / Sign up

Export Citation Format

Share Document